Literature DB >> 3912185

The effects of nifedipine on platelet aggregation and plasma 6-keto-PGF1 alpha, and its interaction with indomethacin.

M B Murphy, M A Orchard, E L Conway, S E Barrow.   

Abstract

Pre-incubation of human platelets with nifedipine in vitro or treatment of normal volunteers with nifedipine, 30 mg daily for one week, did not alter ADP induced aggregation measured by whole blood aggregometry. 6-oxo-Prostaglandin F1 alpha remained undetectable in plasma following oral administration of nifedipine to normal volunteers. The hypotensive response to intravenous nifedipine administration was similar in spontaneously hypertensive rats pretreated with indomethacin or placebo. These results conflict with previous reports that nifedipine alters platelet aggregation and prostaglandin metabolism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3912185     DOI: 10.1007/bf00613454

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

Review 1.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

Authors:  S Moncada; J R Vane
Journal:  Pharmacol Rev       Date:  1978-09       Impact factor: 25.468

2.  Aggregation of blood platelets by adenosine diphosphate and its reversal.

Authors:  G V BORN
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

3.  The effects of nifedipine, a calcium antagonist, on platelet function.

Authors:  J Dale; K H Landmark; E Myhre
Journal:  Am Heart J       Date:  1983-01       Impact factor: 4.749

4.  High-performance liquid chromatography of nifedipine, its metabolites and photochemical degradation products.

Authors:  P Pietta; A Rava; P Biondi
Journal:  J Chromatogr       Date:  1981-06-19

5.  Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

6.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.

Authors:  G A FitzGerald; B Smith; A K Pedersen; A R Brash
Journal:  N Engl J Med       Date:  1984-04-26       Impact factor: 91.245

7.  Dipyridamole inhibits platelet aggregation in whole blood.

Authors:  P Gresele; C Zoja; H Deckmyn; J Arnout; J Vermylen; M Verstraete
Journal:  Thromb Haemost       Date:  1983-12-30       Impact factor: 5.249

8.  Effects of nifedipine (Adalat) on platelet function in vitro and in vivo.

Authors:  H Johnsson
Journal:  Thromb Res       Date:  1981 Feb 15-Mar 1       Impact factor: 3.944

9.  Release of prostacyclin in vivo and its role in man.

Authors:  J M Ritter; S E Barrow; I A Blair; C T Dollery
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

10.  Modification of experimental renal hypertension in the rat by indomethacin and hydralazine.

Authors:  J L Cangiano; C Rodriguez-Sargent; M Martinez-Maldonado
Journal:  J Lab Clin Med       Date:  1978-10
View more
  7 in total

Review 1.  Nifedipine interactions in hypertensive patients.

Authors:  A Salvetti; A Magagna; B Abdel-Haq; M Lenzi; R Giovannetti
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Dose-dependent effects of verapamil and nifedipine on in vivo platelet function in normal volunteers.

Authors:  K Winther; C M Jespersen; B Rydberg; G Thamsborg; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  The effects of intravenous and oral nifedipine on ex vivo platelet function.

Authors:  T J Walley; K L Woods; D B Barnett
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.

Authors:  J L Francis; O S Roath; V F Challenor; D G Waller
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

5.  Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.

Authors:  P Minuz; P Pancera; M Ribul; F Priante; M Degan; A Campedelli; E Arosio; A Lechi
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

6.  Antiplatelet activity of nifedipine is mediated by inhibition of NF-κB activation caused by enhancement of PPAR-β/-γ activity.

Authors:  Ching-Yu Shih; I-Hsin Lin; James-Cheng Ding; Fu-Chi Chen; Tz-Chong Chou
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

7.  Effects of diclofenac on isradipine pharmacokinetics and platelet aggregation in volunteers.

Authors:  D K Sommers; J M Kovarik; E C Meyer; M van Wyk; J R Snyman; M Blom; S Ott; P Grass; K Kutz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.